OpenAlex Citation Counts

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Phillip H. Kuo, Taylor L. Benson, Richard A. Messmann, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 6, pp. 816-818
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Robert Seifert, Louise Emmett, Steven P. Rowe, et al.
European Urology (2023) Vol. 83, Iss. 5, pp. 405-412
Open Access | Times Cited: 139

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 9, pp. 2830-2845
Open Access | Times Cited: 114

PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study
Masatoshi Hotta, Andrei Gafita, Vishnu Murthy, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 7, pp. 1024-1029
Open Access | Times Cited: 28

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Martin Bakht, Himisha Beltran
Nature Reviews Urology (2024)
Closed Access | Times Cited: 15

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)
Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, et al.
Radiology (2024) Vol. 312, Iss. 2
Closed Access | Times Cited: 8

SNMMI Consensus Statement on Patient Selection and Appropriate Use of¹⁷⁷Lu-PSMA-617 Radionuclide Therapy
Thomas A. Hope, Emmanuel S. Antonarakis, Lisa Bodei, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 9, pp. 1417-1423
Open Access | Times Cited: 17

Prostate Cancer Theranostics With 177Lu-PSMA
Hojjat Ahmadzadehfar, Robert Seifert, Ali Afshar‐Oromieh, et al.
Seminars in Nuclear Medicine (2024) Vol. 54, Iss. 4, pp. 581-590
Open Access | Times Cited: 6

Is¹⁸F-FDG PET Needed to Assess¹⁷⁷Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
Robert Seifert, Tuğçe Telli, Boris Hadaschik, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 5, pp. 731-737
Closed Access | Times Cited: 25

Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial
Shay Golan, Michael Frumer, Yarden Zohar, et al.
European Urology Oncology (2022) Vol. 6, Iss. 2, pp. 151-159
Open Access | Times Cited: 24

A VISION Substudy of Reader Agreement on⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for¹⁷⁷Lu-PSMA-617 Radioligand Therapy
Phillip H. Kuo, Don C. Yoo, Ryan Avery, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 8, pp. 1259-1265
Open Access | Times Cited: 13

Real-World Experience with¹⁷⁷Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 5, pp. 735-739
Closed Access | Times Cited: 5

PSMA Radioligand Therapy in Prostate Cancer
Ludmila Santiago Almeida, Elba Etchebehere, Irene García Megías, et al.
Clinical Nuclear Medicine (2023) Vol. 49, Iss. 1, pp. 45-55
Closed Access | Times Cited: 12

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
Kim N., Steven Yip, Glenn Bauman, et al.
Current Oncology (2024) Vol. 31, Iss. 3, pp. 1400-1415
Open Access | Times Cited: 4

Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
Andrei Gafita, Andrew Martin, Louise Emmett, et al.
European Urology Oncology (2024)
Open Access | Times Cited: 4

Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI
David Kersting, Katarzyna Borys, Alina Küper, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Open Access

Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography
Cheng William Hong, Spencer C. Behr, Fei Jiang, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1833-1833
Open Access

Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
Esmée C. A. van der Sar, Adinda J. S. Kühr, Sander C. Ebbers, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1575-1575
Open Access | Times Cited: 17

Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
Daniel Groener, S. Schneider, Justus Baumgarten, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 473-473
Open Access | Times Cited: 10

177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers
Emilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102699-102699
Open Access | Times Cited: 3

RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
Marie Terroir-Cassou-Mounat, Chloé Lamesa, M. Krim, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 754-754
Open Access | Times Cited: 8

Druggability of Targets for Diagnostic Radiopharmaceuticals
Xinyu Wang, Chongyang Chen, Junjie Yan, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 8, pp. 1107-1119
Open Access | Times Cited: 7

Role of Ga68 Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Prostate Cancer Imaging
Jaykanth Amalachandran, Thangalakshmi Sivathapandi, G. Gunasekaran
Deleted Journal (2024) Vol. 07, Iss. 02, pp. 121-147
Open Access | Times Cited: 2

Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment
Franz von Stauffenberg, Cédric Poyet, Stephan Beintner-Skawran, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4263-4263
Open Access | Times Cited: 2

Eligibility for¹⁷⁷Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of⁶⁸Ga-PSMA-11 and^99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer
Gary Cook, Wai‐Lup Wong, Bal Sanghera, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 2, pp. 227-231
Open Access | Times Cited: 9

Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy
Hossein Jadvar, Patrick M. Colletti
Journal of Nuclear Medicine Technology (2023) Vol. 51, Iss. 1, pp. 16-21
Open Access | Times Cited: 5

Page 1 - Next Page

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSID	session	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.

Requested Article:

Showing 1-25 of 37 citing articles:

Your Privacy